Eileen Oldfield, Associate Editor, Pharmacy Times

Chronic myeloid leukemia patients likely have comorbid conditions at the time of their diagnosis; however, most tyrosine-kinase inhibitor studies exclude patients with these conditions.

HIV positive patients who become distressed more easily may be less likely to adhere to antiretroviral treatment (ART), suggest the results of a study appearing in the September 2013 edition of Behavior Therapy.

A recent study compared the annual cost per treated patient for a health plan for patients taking etanercept, adalimumab, or infliximab.

The Generic Pharmaceutical Association petition recommends that the FDA use the active ingredient in a reference biologic when naming a biosimilar product.

A study compared historical and contemporary multiple sclerosis cases to determine how first-generation disease-modifying drugs affected disease progression.

The Patients' Access to Treatments Act of 2013 proposes limits on patients' costs for specialty drugs.

Data from a national survey on community health in racial and ethnic groups suggest specific socioeconomic barriers to hepatitis C virus detection and therapy.

Another state sets up the pathway for biosimilar substitution; however, the proposed legislation comes with restrictions on that practice.

An assessment of costs and specialty drug use within 4 chronic conditions found specialty drugs contribute to overall costs for insurance plan members.

Agency aims for consistent biosimilar evaluation procedures, while future in US remains unknown.

In a new study published in the Journal of Managed Care Pharmacy, investigators interviewed patients and pharmacists about the costs and benefits of obtaining antiretroviral therapies from a community pharmacy.

As the federal budgetary ax falls, tax credits for drugs to treat orphan disease may become victim to government spending cuts.

The Academy of Managed Care Pharmacy (AMCP) recommended an expanded role for managed care and specialty pharmacists as the FDA re-evaluates its mandated Risk Evaluation and Mitigation Strategies (REMS) program.

Experience with biologics and biosimilar products means a high level of trust from US payers, according to a report from BioTrends Research Group.

A bill passed by the Florida legislature would allow pharmacists to substitute biosimilars for brand-named biologics provided that a number of criteria are met.

The FDA's restricted distribution programs, intended for medications with toxicity risks or other potential dangers, may also be used to impede biosimilar competition, according to a Federal Trade Commission amicus brief filed in the US District Court for the District of New Jersey.